TAA-05 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TAA-05’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TAA-05 overview

TAA-05 is under development for the treatment of relapsed and refractory acute myelocytic leukemia. The drug candidate comprises of autologous T cells genetically engineered to express a chimeric antigen receptor acts by targeting  FLT3 autologous chimeric antigen receptor T cells. It is administered through intravenous route.

PersonGen BioTherapeutics (Suzhou) overview

PersonGen BioTherapeutics (Suzhou) (PersonGen) is a biotechnology company focused on developing CAR-related therapies, analytical antibodies, novel CAR-T therapeutics, and allogeneic cellular therapies. PersonGen is headquartered in Suzhou, Jiangsu, China.

For a complete picture of TAA-05’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.